Drug intelligence / Profile preview

prednisone + chloroquine

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of prednisone (a corticosteroid) and chloroquine (an antimalarial drug). This combination has been studied as an alternative treatment for autoimmune hepatitis (AIH), particularly for patients who are non-responders or partial responders to standard therapy, or who experience side effects from standard treatments. It has also been used in treating lupus to reduce the amount of steroid needed to control symptoms.

Targets

GR (Glucocorticoid receptor)β-Hematin

Beyond the preview

Go deeper on prednisone + chloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisone + chloroquine.

Explore the full profile